bioRxivBioengineeringPreprint
The thermostability of a VADEX-Pro based protein nanoparticle
Abstract
We have adapted split GFP technology into the protein nanoparticle platform, Vaccine Delivery system X (VADEX), created in previous study. To evaluate the capability of this new platform, a model protein, maltose binding protein (MBP), was fused to the {beta}-strand 11 of sfGFP and co-expressed with VADEX-10 which was composed of LYRRLE peptide and N-terminal part up to {beta}-strand 10 of sfGFP. When these two fusion proteins were expressed in a cell, they were assembled into PNP spontaneously with a dynamic light scattering (DLS) particle size of 26 nm. This nanoparticle platform was renamed as VADEX-Pro for its capacity of expressing large protein on PNP. The thermostability of the assembled PNP was verified by both SDS-PAGE and DLS analysis following treatment. This PNP was stable at 25 {degrees}C and at temperatures as high as 40 {degrees}C for at least two months. Mutations that replaced cysteine residue of the LYRRLE peptide with serine or alanine destabilized and induced degradation of the VADEX-based PNP. The results in this study showed that the non-covalent complementation of split sfGFP became irreversible when reconstituted sfGFP was assembled in a VADEX-Pro PNP. This platform may be applied in developing thermostable vaccines.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A thermally stable protein nanoparticle that stimulates long lasting humoral immune response
T.-T. Wong, G.-G. Liou, M.-C. Kan·bioRxiv·Dec 30, 2022
- A self-assembled protein nanoparticle serving as a one-shot vaccine carrier
M.-C. Kan, T.-T. Wong, G.-G. Liou·bioRxiv·Sep 16, 2020
- Lyophilized yeast powder for adjuvant free thermostable vaccine delivery
Ravinder Kumar, Bhushan N. Kharbikar·Applied Microbiology and BiotechnologyPeer-reviewed·Apr 1, 2021
- Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine
Melissa Anne Edeling, Linda Earnest, … Joseph Torresi·bioRxiv·Mar 12, 2026
- A low-cost, thermostable, cell-free protein synthesis platform for on demand production of conjugate vaccines
Katherine F. Warfel, Asher J. Williams, … Michael C. Jewett·ACS Synthetic BiologyPeer-reviewed·Dec 22, 2022
- A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response
A. Gerhardt, E. Voigt, … C. Casper·bioRxiv·Feb 1, 2021